HCW Biologics Inc. filings document a clinical-stage biopharmaceutical issuer developing fusion immunotherapeutics through the TOBI and TRBC platforms. Its SEC records include 8-K reports for operating results, clinical and regulatory program updates, material agreements, licensing activity and Nasdaq-related corporate events, along with registration statements covering securities offerings and related capital-structure disclosures.
HCWB proxy and governance filings describe annual meeting matters, shareholder voting procedures and bylaw amendments, including quorum provisions. The company’s formal disclosures also address product-candidate development, financial condition, emerging growth company status, risk factors, ownership and governance controls relevant to its public-company reporting profile.
HCW Biologics Inc. is registering up to 13,625,304 shares of common stock, up to 13,625,304 pre-funded warrants, and 13,625,304 shares underlying those warrants in a primary offering for gross proceeds of about $5.6 million on a reasonable best efforts basis.
The assumed offering price is $0.411 per share, matching the April 20, 2026 Nasdaq close. Common shares outstanding are 6,734,104 and would rise to 20,359,408 if only stock (no pre-funded warrants) is sold. Existing holders face immediate dilution, and there is no minimum raise or escrow, so the company may collect far less than the maximum.
Pre-funded warrants are aimed at investors otherwise exceeding 4.99% or 9.99% ownership caps and carry a $0.0001 exercise price with no expiry. Net proceeds are expected to be about $5.2 million at the full size, to fund clinical and preclinical development, including HCW9302 trials, R&D, marketing and general corporate uses. The company has recent Nasdaq bid-price and equity compliance history and a May 5, 2026 hearing regarding minimum bid price.
HCW Biologics Inc. is soliciting proxies for its 2026 virtual Annual Meeting on June 15, 2026 to elect Class II directors, ratify Crowe LLP as auditor, and seek shareholder approval for three corporate actions: a Board-authorized reverse stock split (range 1-for-5 to 1-for-20) to help maintain Nasdaq listing; approval to permit issuance upon exercise of up to 2,477,292 Common Warrants issued in February 2026; and approval to reprice and permit issuance upon exercise of up to 3,020,410 Existing Warrants to an exercise price of $0.6055 (reduced from $2.41).
The Board fixed the record date as April 22, 2026. The Company states Armistice invested $17.4 million under the February 2026 financing and that Proposals Four and Five must be re-submitted every 60 days until approved. The Board recommends a vote FOR all proposals.
HCW Biologics Inc. is changing its corporate rules to make it easier to conduct shareholder meetings. On April 15, 2026, the board approved a Bylaw amendment that, effective April 28, 2026, lowers the quorum needed to do business at stockholder meetings.
Going forward, holders of 33 1/3% of the voting power, present in person or by proxy, will be enough to constitute a quorum. Previously, the Bylaws required a majority of the voting power of outstanding shares entitled to vote to be present for business to proceed.
HCW Biologics Inc. presents an in-depth business overview as a clinical-stage immunotherapy company focused on diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated dysplasia.
The company’s lead candidate HCW9302, an IL‑2 fusion protein, entered a Phase 1 trial in alopecia areata in November 2025, with two active U.S. sites and ongoing dose escalation to establish a recommended Phase 2 dose. Preclinical programs include the “Big BiTE” T‑cell engager HCW11‑018b for solid tumors and checkpoint fusion HCW11‑040 initially targeting bronchopulmonary dysplasia.
HCW highlights commercial‑ready reagents HCW9206 and HCW9201 for CAR‑T and NK cell manufacturing, extensive patent coverage for its TOBI and TRBC platforms, and out‑licensing deals with Wugen and Trimmune. As of March 25, 2026, common shares outstanding total 6,734,104, and non‑affiliate equity value was about $6.2 million as of June 30, 2025.
HCW Biologics Inc. reported fourth quarter and full-year 2025 results showing very limited revenue and ongoing losses alongside financing and listing pressures. Revenue was $27,010 for the quarter and $54,232 for 2025, down sharply from $2.6 million in 2024, mainly due to changes in a licensing arrangement.
The company cut operating expenses to $13.2 million in 2025 from $30.4 million in 2024, helped by a $5.5 million gain tied to resolving prior legal fees. Net loss improved to $7.96 million in 2025 from $30.0 million in 2024, but cash fell to $1.95 million as of December 31, 2025.
Management states that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months without new funding. HCW also received a new Nasdaq notice on March 26, 2026 for failing to maintain the $1 minimum bid price after a prior reverse stock split and plans to appeal. On the business side, the company initiated a Phase 1 trial of its lead autoimmune candidate HCW9302 in alopecia areata and received a $3.5 million upfront fee for licensing preclinical molecule HCW11-006, plus a minority equity stake and potential milestones and royalties.
HCW Biologics Inc. entered a material license agreement for its fusion immunotherapy candidate HCW11-006, securing an upfront license fee valued at $7.0 million. This consists of a $3.5 million cash payment and a $3.5 million in-kind payment via a transferable equity interest in its licensee, Beijing Trimmune Biotech.
Trimmune will lead development and commercialization of HCW11-006, with a Phase 1 clinical study in China expected in the first half of 2027 and will bear all trial costs. HCW Biologics remains eligible for development milestone payments, double-digit royalties on future product sales, and a share of proceeds from future transactions involving HCW11-006.
The company also negotiated a payment-, milestone-, and royalty-free option to recapture rights to HCW11-006 for in vivo use in the United States, Canada, Central America and South America after completion of the Phase 1 study in China, and granted Trimmune an option to license regional China rights to its clinical-stage molecule HCW9302.
HCW Biologics Inc. is calling a virtual special stockholder meeting on April 27, 2026 to approve two warrant-related actions tied to a recent follow-on public offering.
Proposal One seeks approval, under Nasdaq Listing Rule 5635(d), for the issuance of up to 2,477,292 shares of common stock upon exercise of Common Stock Purchase Warrants issued in the February 2026 unit offering. Without approval, warrant exercises are capped at 1,646,056 shares, or about 19.99% of pre-deal outstanding shares.
Proposal Two asks stockholders to approve repricing previously issued warrants covering up to 3,020,410 shares, reducing the exercise price from $2.41 to $0.6055 per share and approving share issuance upon exercise. The company explains that approval of both proposals could significantly dilute existing stockholders’ economic and voting interests but may improve the likelihood of warrant exercises, provide additional capital, and support continued Nasdaq listing compliance. The board recommends voting FOR both proposals.
HCW Biologics Inc. is asking stockholders to approve two Nasdaq-related actions at a virtual Special Meeting on April 27, 2026: permission to issue up to 2,477,292 shares upon exercise of Common Warrants issued in the February 2026 follow-on offering, and approval to reprice Prior Warrants to an exercise price of $0.6055 enabling issuance of up to 3,020,410 shares if exercised. The Board recommends a FOR vote on both proposals. The record date for voting is March 3, 2026, and materials will be mailed beginning on or about March 13, 2026.
HCW Biologics Inc. reports that a Nasdaq Hearings Panel determined on February 26, 2026 that the company has regained compliance with all continued listing rules of The Nasdaq Capital Market. This follows an earlier Panel decision that gave HCW Biologics until December 31, 2025 to meet the Equity Rule 5550(b)(1) and until February 16, 2026 to satisfy all other listing standards.
The company will remain under a one-year Mandatory Panel Monitor starting January 7, 2026. If it again falls out of compliance with the Equity Rule during this period, Nasdaq staff must issue a delist determination without providing any cure or additional compliance period, though the company could request a new hearing. Management highlighted that maintaining compliance supports ongoing access to public capital markets to fund its clinical-stage immunotherapy programs.
HCW Biologics Inc. entered into a follow-on public offering of 2,477,292 units at $0.6055 per unit, raising approximately $1.5 million in gross proceeds. Each unit includes one share of common stock or a pre-funded warrant plus one common stock warrant.
The common stock warrants carry a $0.6055 exercise price, become exercisable only after stockholder approval under Nasdaq rules, and expire five years after that approval. Pre-funded warrants are exercisable immediately at $0.0001 per share and remain outstanding until fully exercised.
The company also agreed, subject to stockholder approval, to reduce the exercise price of existing warrants to purchase up to 3,020,410 shares from $2.41 to $0.6055 per share. Net proceeds are intended for preclinical and clinical development, including trials for lead candidate HCW9302, and for general corporate purposes.